Hedge funds have recently made changes to their positions in the business. Sei Investments Co. increased its stake in Insmed by 2.4% during the 4th quarter. Sei Investments Co. now owns 31,000 shares of the biopharmaceutical company’s stock valued at $737,000 after purchasing an additional 736 shares in the last quarter. Principal Financial Group Inc. increased its position in Insmed by 0.4% during the fourth quarter. Principal Financial Group Inc. now owns 217,844 shares of the biopharmaceutical company’s stock worth $5,203,000 after purchasing an additional 765 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Insmed by 17.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,818 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 854 shares during the last quarter. Evolution Wealth Advisors LLC increased its position in Insmed by 915.7% during the fourth quarter. Evolution Wealth Advisors LLC now owns 1,097 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 989 shares during the last quarter. Finally, UBS Asset Management Americas Inc. increased its position in Insmed by 1.8% during the fourth quarter. UBS Asset Management Americas Inc. now owns 89,873 shares of the biopharmaceutical company’s stock worth $2,146,000 after purchasing an additional 1,581 shares during the last quarter.
PS: Remember the value shown here was before the recent $30+/shr move.